Due to the reported safety concerns, we aimed to perform a systematic review and meta-analysis to determine the effect of preadmission/pre-diagnosis use of calcium channel blockers (CCBs) on the clinical outcomes in patients with COVID-19. A systematic literature search with no language restriction was conducted in electronic databases in July 2021 to identify eligible studies. The outcomes of interest were all-cause mortality and severe illness. A random-effects model was used to estimate the pooled summary measure for outcomes of interest with the preadmission/pre-diagnosis use of CCBs relative to non-use CCBs, at 95% confidence intervals (CIs). The meta-analyses revealed no significant difference in the odds of all-cause mortality (pooled OR=0.82; 95% CI 0.68–1.00; n=58,355) and in the odds of severe illness (pooled OR=0.83; 95% CI 0.61–1.15; n=46,091) respectively, with preadmission/pre-diagnosis use of CCBs relative to non-use of CCBs. Nevertheless, subgroup analysis of studies originated from East Asia reported a significant reduction in the odds of all-cause mortality (pooled OR=0.50; 95% CI 0.37–0.68) and the odds of severe illness (pooled OR=0.51; 95% CI 0.33–0.78). There may be no safety concerns with the use of CCBs in patients with COVID-19, but their potential protective effects in the East Asian patients merit further investigations.